Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Single Centre, Double-Blind, Randomised, Placebo- Controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Inhaled Doses of AZD8683 in Healthy Volunteers and COPD Patients

NCT01584739 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01584739
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01584739 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Single Centre, Double-Blind, Randomised, Placebo- Controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Inhaled Doses of AZD8683 in Healthy Volunteers and COPD Patients
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Terminated
Start date
June 30, 2012
Completion date
November 30, 2012
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

copd